Halozyme(US:HALO)2026-03-10 18:02Halozyme Therapeutics Conference Call Summary Company Overview - Company: Halozyme Therapeutics (NasdaqGS: HALO) - Date: March 10, 2026 - Event: Leerink's Global Healthcare Conference Key Points Recent Acquisitions - Halozyme executed two acquisitions: Elektrofi and Surf Bio, aimed at enhancing subcutaneous drug delivery capabilities [2][4] - The acquisitions are expected to broaden and diversify offerings for partners in the biologics market [2][4] ENHANZE Technology - ENHANZE is a core technology that allows for large volume subcutaneous delivery of biologics, with 10 approved products and multiple in development [7] - The technology enables injections of 5-15 mL in minutes, enhancing patient convenience and treatment adherence [7][17] - The company anticipates signing 1-3 new ENHANZE deals in 2026, driven by increased interest in subcutaneous delivery [15][20] Hyperconcentration Technology - Hyperconcentration technology allows biologics to be concentrated by 3-4 times, facilitating smaller volume injections (2 mL or less) [4][11] - Clinical scale batches are expected to be ready this year, with two partners anticipated to enter Phase 1 testing [13] - The company projects achieving $1 billion in royalty revenue from Hyperconcentration by the mid-2030s [27][29] Market Trends and Growth Drivers - There is a growing recognition among pharmaceutical companies of the competitive advantages of subcutaneous delivery, leading to increased market interest [16][20] - Examples of successful subcutaneous products include Darzalex, VYVGART, and Ocrevus, which have seen significant market growth due to their delivery methods [17][18][19] M&A Strategy - Halozyme is focused on disciplined M&A, targeting opportunities that align with its business model of recurring, royalty-like revenues [21][25] - The company is patient in evaluating potential acquisitions, looking for businesses that complement its growth story [24][25] Financial Performance - In 2025, Halozyme reported a revenue growth of 38% to $1.4 billion, with royalties growing by 52% [38] - A one-time charge related to the Surf Bio acquisition impacted fourth-quarter EPS, but the company expects strong growth moving forward [38][39] Legal Matters - Halozyme is involved in litigation against Merck for patent infringement related to its Mdase patents, with potential for damages and injunctive relief [45][46] - The company does not expect significant impact from this litigation on its current projections [45] Future Outlook - The company anticipates doubling the number of commercialized and development products from about 20 to 40 by 2028 [54] - Strong growth is expected from existing products, including Darzalex, VYVGART, and RYBREVANT, which is projected to become a significant contributor due to its subcutaneous formulation [55][57] Regulatory Environment - Halozyme is monitoring the implications of the IRA (Inflation Reduction Act) on its products, expecting minimal impact due to the nature of its drug indications [33][36] Conclusion - Halozyme is positioned for significant growth through its innovative technologies, strategic acquisitions, and a strong market presence in subcutaneous drug delivery. The company is optimistic about its future prospects and continues to explore opportunities for expansion while maintaining a disciplined approach to M&A.